Effects of Risankizumab on Nail Psoriasis in Patients with Active Psoriatic Arthritis: Results from KEEPsAKE‐1

2022 ◽  
Author(s):  
Lars Erik Kristensen ◽  
Ahmed M. Soliman ◽  
Kim Papp ◽  
Joseph F. Merola ◽  
Lisa Barcomb ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Nail Psoriasis

Usefulness of dual-energy computed tomography for the evaluation of early-stage psoriatic arthritis only accompanied by nail psoriasis

2017 ◽  
Vol 44 (12) ◽  
pp. e326-e327 ◽  
Author(s):  
Akihiko Asahina ◽  
Takeshi Fukuda ◽  
Yozo Ishiuji ◽  
Aya Yaginuma ◽  
Koichi Yanaba ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Psoriatic Arthritis ◽  
Early Stage ◽  
Dual Energy ◽  
Nail Psoriasis ◽  
Dual Energy Computed Tomography

Psoriatic Nail Disease: Quality of Life and Treatment

2009 ◽  
Vol 13 (5_suppl) ◽  
pp. S102-S106 ◽  
Author(s):  
Aditya K. Gupta ◽  
Elizabeth A. Cooper
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Plaque Psoriasis ◽  
Large Scale ◽  
Severity Index ◽  
Biologic Therapies ◽  
Nail Psoriasis ◽  
Psoriatic Nail Disease

Nail psoriasis is common among patients with plaque psoriasis or psoriatic arthritis and has a detrimental effect on quality of life. However, there are currently no standardized therapeutic regimens for nail psoriasis. Traditional treatments for nail psoriasis, which include topical, intralesional, and oral therapies, may be time-consuming, painful, or unsafe when administered long term. Biologic therapies have demonstrated efficacy for plaque psoriasis and psoriatic arthritis; these therapies may be particularly promising for the treatment of nail psoriasis as both groups of patients have an elevated incidence of nail dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically important nail psoriasis improvements using the Nail Psoriasis Severity Index, a helpful tool that, upon validation, will allow comparison across treatments and trials. Large-scale, long-term trials using standardized outcome measures are needed to further evaluate biologic therapies for the treatment of nail psoriasis.

25851 Efficacy of secukinumab in managing axial manifestations and nail psoriasis in patients with psoriatic arthritis: Results from the MAXIMISE trial

2021 ◽  
Vol 85 (3) ◽  
pp. AB72
Author(s):  
Alice B. Gottlieb ◽  
Xenofon Baraliakos ◽  
Laura C. Coates ◽  
Effie Pournara ◽  
Michael Rissler ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Nail Psoriasis

Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis

2019 ◽  
Vol 36 (3) ◽  
pp. 384-385 ◽  
Author(s):  
Leah Ellis Wells ◽  
Tyler Evans ◽  
Rachael Hilton ◽  
Lara Wine Lee ◽  
Natasha Ruth
Keyword(s):  
Psoriatic Arthritis ◽  
Pediatric Patient ◽  
Nail Psoriasis
Sign in / Sign up

Export Citation Format

Share Document